Schnekenburger and colleagues showed that their newly synthesized Compound 18 (identified via in silico screening, see Section 3.8) inhibits SIRT-1 and SIRT-2 with an anti-proliferative effect in glioma cells, both in in vitro and in vivo settings [197]. Here, SIRT2 is linked to central nervous system cancer.